Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Chimeric antigen receptor engineered stem cells: a novel HIV therapy.

Literature DB >> 28357916

Chimeric antigen receptor engineered stem cells: a novel HIV therapy.

Anjie Zhen¹, Mayra A Carrillo¹, Scott G Kitchen¹.

Abstract

Despite the success of combination antiretroviral therapy (cART) for suppressing HIV and improving patients' quality of life, HIV persists in cART-treated patients and remains an incurable disease. Financial burdens and health consequences of lifelong cART treatment call for novel HIV therapies that result in a permanent cure. Cellular immunity is central in controlling HIV replication. However, HIV adopts numerous strategies to evade immune surveillance. Engineered immunity via genetic manipulation could offer a functional cure by generating cells that have enhanced antiviral activity and are resistant to HIV infection. Recently, encouraging reports from several human clinical trials using an anti-CD19 chimeric antigen receptor (CAR) modified T-cell therapy for treating B-cell malignancies have provided valuable insights and generated remarkable enthusiasm in engineered T-cell therapy. In this review, we discuss the development of HIV-specific chimeric antigen receptors and the use of stem cell based therapies to generate lifelong anti-HIV immunity.

Entities: Disease Gene Species

Keywords: Chimeric antigen receptors, engineered immunity; HIV cytotoxic T lymphocytes (CTL); HIV infection; HIV therapy; stem cell-based gene therapy

Mesh：

Substances：

Year: 2017 PMID： 28357916 PMCID： PMC5618937 DOI： 10.2217/imt-2016-0121

Source DB: PubMed Journal: Immunotherapy ISSN： 1750-743X Impact factor: 4.196

74 in total

1. Antitumor activity from antigen-specific CD8 T cells generated in vivo from genetically engineered human hematopoietic stem cells.

Authors: Dimitrios N Vatakis; Richard C Koya; Christopher C Nixon; Liu Wei; Sohn G Kim; Patricia Avancena; Gregory Bristol; David Baltimore; Donald B Kohn; Antoni Ribas; Caius G Radu; Zoran Galic; Jerome A Zack
Journal: Proc Natl Acad Sci U S A Date: 2011-11-28 Impact factor: 11.205

2. HIV-1 Nef protein protects infected primary cells against killing by cytotoxic T lymphocytes.

Authors: K L Collins; B K Chen; S A Kalams; B D Walker; D Baltimore
Journal: Nature Date: 1998-01-22 Impact factor: 49.962

3. A phase II randomized study of HIV-specific T-cell gene therapy in subjects with undetectable plasma viremia on combination antiretroviral therapy.

Authors: Steven G Deeks; Bridget Wagner; Peter A Anton; Ronald T Mitsuyasu; David T Scadden; Christine Huang; Catherine Macken; Douglas D Richman; Cindy Christopherson; Carl H June; Richard Lazar; David F Broad; Sayeh Jalali; Kristen M Hege
Journal: Mol Ther Date: 2002-06 Impact factor: 11.454

4. Different cytokine and stimulation conditions influence the expansion and immune phenotype of third-generation chimeric antigen receptor T cells specific for tumor antigen GD2.

Authors: Tessa Gargett; Michael P Brown
Journal: Cytotherapy Date: 2015-01-06 Impact factor: 5.414

Review 5. Current advances in humanized mouse models.

Authors: Ryoji Ito; Takeshi Takahashi; Ikumi Katano; Mamoru Ito
Journal: Cell Mol Immunol Date: 2012-02-13 Impact factor: 11.530

6. Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19.

Authors: James N Kochenderfer; Wyndham H Wilson; John E Janik; Mark E Dudley; Maryalice Stetler-Stevenson; Steven A Feldman; Irina Maric; Mark Raffeld; Debbie-Ann N Nathan; Brock J Lanier; Richard A Morgan; Steven A Rosenberg
Journal: Blood Date: 2010-07-28 Impact factor: 22.113

7. Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains.

Authors: Carmine Carpenito; Michael C Milone; Raffit Hassan; Jacqueline C Simonet; Mehdi Lakhal; Megan M Suhoski; Angel Varela-Rohena; Kathleen M Haines; Daniel F Heitjan; Steven M Albelda; Richard G Carroll; James L Riley; Ira Pastan; Carl H June
Journal: Proc Natl Acad Sci U S A Date: 2009-02-11 Impact factor: 11.205

8. HIV-1-Specific Chimeric Antigen Receptors Based on Broadly Neutralizing Antibodies.

Authors: Ayub Ali; Scott G Kitchen; Irvin S Y Chen; Hwee L Ng; Jerome A Zack; Otto O Yang
Journal: J Virol Date: 2016-07-11 Impact factor: 5.103

Review 9. CD19-CAR trials.

Authors: Carlos A Ramos; Barbara Savoldo; Gianpietro Dotti
Journal: Cancer J Date: 2014 Mar-Apr Impact factor: 3.360

Review 10. Improving the safety of cell therapy products by suicide gene transfer.

Authors: Benjamin S Jones; Lawrence S Lamb; Frederick Goldman; Antonio Di Stasi
Journal: Front Pharmacol Date: 2014-11-27 Impact factor: 5.810

9 in total

1. Long-term survival and differentiation of human thymocytes in human thymus-grafted immunodeficient mice.

Authors: Yang Tang; Yong-Guang Yang; Ou Bai; Jinxing Xia; Zheng Hu
Journal: Immunotherapy Date: 2019-05-29 Impact factor: 4.196

Review 2. Advances in engineering local drug delivery systems for cancer immunotherapy.

Authors: Peter Abdou; Zejun Wang; Qian Chen; Amanda Chan; Daojia R Zhou; Vivienne Gunadhi; Zhen Gu
Journal: Wiley Interdiscip Rev Nanomed Nanobiotechnol Date: 2020-04-07

3. Novel Triterpenone for Treatment of Viral Diseases-HIV Inhibitors.

Authors: Robert B Kargbo
Journal: ACS Med Chem Lett Date: 2018-03-14 Impact factor: 4.345

4. Chronic virus infection drives CD8 T cell-mediated thymic destruction and impaired negative selection.

Authors: Heidi J Elsaesser; Mahmood Mohtashami; Ivan Osokine; Laura M Snell; Cameron R Cunningham; Giselle M Boukhaled; Dorian B McGavern; Juan Carlos Zúñiga-Pflücker; David G Brooks
Journal: Proc Natl Acad Sci U S A Date: 2020-02-24 Impact factor: 11.205